The generative AI in personalized medicine market is experiencing rapid growth, fueled by advances in AI-driven drug discovery, genomic analysis, and tailored treatment planning. With a projected CAGR of over 38% through 2034, this market is reshaping how healthcare providers deliver faster, more accurate, and affordable solutions for patients worldwide.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Generative AI in Personalized Medicine Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Generative AI in Personalized Medicine Market, by Personalized Medicine Therapeutics
8.1.1 Pharmaceutical
8.1.1.1. Market Revenue and Forecast
8.1.2. Genomic Medicine
8.1.2.1. Market Revenue and Forecast
8.1.3. Devices
8.1.3.1. Market Revenue and Forecast
9.1. Generative AI in Personalized Medicine Market, by Deployment Model
9.1.1. On-premise
9.1.1.1. Market Revenue and Forecast
9.1.2. Cloud Based
9.1.2.1. Market Revenue and Forecast
10.1. Generative AI in Personalized Medicine Market, by End-User
10.1.1. Hospitals and Clinics
10.1.1.1. Market Revenue and Forecast
10.1.2. Clinical Research
10.1.2.1. Market Revenue and Forecast
10.1.3. Healthcare Organizations
10.1.3.1. Market Revenue and Forecast
10.1.4. Diagnostic Centers
10.1.4.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics
11.1.2. Market Revenue and Forecast, by Deployment Model
11.1.3. Market Revenue and Forecast, by End-User
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics
11.1.4.2. Market Revenue and Forecast, by Deployment Model
11.1.4.3. Market Revenue and Forecast, by End-User
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics
11.1.5.2. Market Revenue and Forecast, by Deployment Model
11.1.5.3. Market Revenue and Forecast, by End-User
11.2. Europe
11.2.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics
11.2.2. Market Revenue and Forecast, by Deployment Model
11.2.3. Market Revenue and Forecast, by End-User
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics
11.2.4.2. Market Revenue and Forecast, by Deployment Model
11.2.4.3. Market Revenue and Forecast, by End-User
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics
11.2.5.2. Market Revenue and Forecast, by Deployment Model
11.2.5.3. Market Revenue and Forecast, by End-User
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics
11.2.6.2. Market Revenue and Forecast, by Deployment Model
11.2.6.3. Market Revenue and Forecast, by End-User
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics
11.2.7.2. Market Revenue and Forecast, by Deployment Model
11.2.7.3. Market Revenue and Forecast, by End-User
11.3. APAC
11.3.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics
11.3.2. Market Revenue and Forecast, by Deployment Model
11.3.3. Market Revenue and Forecast, by End-User
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics
11.3.4.2. Market Revenue and Forecast, by Deployment Model
11.3.4.3. Market Revenue and Forecast, by End-User
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics
11.3.5.2. Market Revenue and Forecast, by Deployment Model
11.3.5.3. Market Revenue and Forecast, by End-User
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics
11.3.6.2. Market Revenue and Forecast, by Deployment Model
11.3.6.3. Market Revenue and Forecast, by End-User
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics
11.3.7.2. Market Revenue and Forecast, by Deployment Model
11.3.7.3. Market Revenue and Forecast, by End-User
11.4. MEA
11.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics
11.4.2. Market Revenue and Forecast, by Deployment Model
11.4.3. Market Revenue and Forecast, by End-User
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics
11.4.4.2. Market Revenue and Forecast, by Deployment Model
11.4.4.3. Market Revenue and Forecast, by End-User
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics
11.4.5.2. Market Revenue and Forecast, by Deployment Model
11.4.5.3. Market Revenue and Forecast, by End-User
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics
11.4.6.2. Market Revenue and Forecast, by Deployment Model
11.4.6.3. Market Revenue and Forecast, by End-User
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics
11.4.7.2. Market Revenue and Forecast, by Deployment Model
11.4.7.3. Market Revenue and Forecast, by End-User
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics
11.5.2. Market Revenue and Forecast, by Deployment Model
11.5.3. Market Revenue and Forecast, by End-User
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics
11.5.4.2. Market Revenue and Forecast, by Deployment Model
11.5.4.3. Market Revenue and Forecast, by End-User
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Personalized Medicine Therapeutics
11.5.5.2. Market Revenue and Forecast, by Deployment Model
11.5.5.3. Market Revenue and Forecast, by End-User
12.1. Butterfly Network
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Deep Genomics
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Google LLC
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. IBM Watson Health
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Microsoft Corporation
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Aidoc
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Insilico Medicine
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. PathAI
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Tencent Holdings Ltd.
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Neuralink Corporation
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description